CR20220175A - Combinación farmacéutica de inhibidores de PRMT5 - Google Patents
Combinación farmacéutica de inhibidores de PRMT5Info
- Publication number
- CR20220175A CR20220175A CR20220175A CR20220175A CR20220175A CR 20220175 A CR20220175 A CR 20220175A CR 20220175 A CR20220175 A CR 20220175A CR 20220175 A CR20220175 A CR 20220175A CR 20220175 A CR20220175 A CR 20220175A
- Authority
- CR
- Costa Rica
- Prior art keywords
- inhibitor
- pharmaceutical combination
- kras
- prmt5
- prmt5 inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente divulgación se refiere a combinaciones farmacéuticas para tratar y/o prevenir el cáncer y métodos y usos de las mismas. Más particularmente, se proporcionan una combinación farmacéutica que comprende un inhibidor de PRMT5 y un modulador de la actividad celular seleccionado de un inhibidor de EGFR, un inhibidor de KRAS, un inhibidor de KRAS-G12C, un inhibidor de MEK, un inhibidor de Bcl-2, un inhibidor de SOS1, un inhibidor de PARP, un inhibidor de RAF, un inhibidor de ERK, un inhibidor de CDK4/6, un inhibidor de MALT1, un inhibidor de BTK, un inhibidor de MAT2A, un inhibidor de PI3K, un inhibidor de AKT, un inhibidor de FGFR, un inhibidor de PRMT de tipo I, un agonista de STING o un inhibidor/modulador del punto de control inmunitario.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201921042899 | 2019-10-22 | ||
PCT/IB2020/059921 WO2021079302A1 (en) | 2019-10-22 | 2020-10-22 | Pharmaceutical combination of prmt5 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20220175A true CR20220175A (es) | 2022-06-21 |
Family
ID=73198360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20220175A CR20220175A (es) | 2019-10-22 | 2020-10-22 | Combinación farmacéutica de inhibidores de PRMT5 |
Country Status (16)
Country | Link |
---|---|
US (1) | US20220395508A1 (es) |
EP (1) | EP4048270A1 (es) |
JP (1) | JP2023504230A (es) |
KR (1) | KR20220086628A (es) |
CN (1) | CN114599361A (es) |
AU (1) | AU2020371295A1 (es) |
BR (1) | BR112022007808A2 (es) |
CA (1) | CA3156135A1 (es) |
CO (1) | CO2022005053A2 (es) |
CR (1) | CR20220175A (es) |
EC (1) | ECSP22032209A (es) |
IL (1) | IL292229A (es) |
MX (1) | MX2022004917A (es) |
PE (1) | PE20221154A1 (es) |
WO (1) | WO2021079302A1 (es) |
ZA (1) | ZA202203770B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL307393A (en) * | 2021-04-08 | 2023-12-01 | Mirati Therapeutics Inc | Combination therapies used in PRMT5 inhibitors to treat cancer |
WO2022216648A1 (en) * | 2021-04-08 | 2022-10-13 | Mirati Therapeutics, Inc. | Combination therapies using prmt5 inhibitors for the treatment of cancer |
AU2022316200A1 (en) * | 2021-07-20 | 2024-01-25 | Inspirna, Inc. | Compositions and methods for inhibiting creatine transport as a treatment for cancer |
WO2023001133A1 (zh) * | 2021-07-20 | 2023-01-26 | 上海齐鲁制药研究中心有限公司 | Prmt5抑制剂 |
WO2023131305A1 (zh) * | 2022-01-06 | 2023-07-13 | 江苏先声药业有限公司 | Prmt5抑制剂和抗癌治疗剂的组合 |
CN116655638B (zh) * | 2022-05-12 | 2024-01-26 | 上海齐鲁制药研究中心有限公司 | 氘代prmt5抑制剂 |
CN116211869B (zh) * | 2022-12-07 | 2023-08-01 | 浙江省肿瘤医院 | 含dna损伤修复抑制剂的药物混合物及混合方法、用途 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0922332D0 (en) | 2009-12-22 | 2010-02-03 | Isis Innovation | Method of treatment and screening method |
WO2011079236A1 (en) | 2009-12-22 | 2011-06-30 | The Ohio State University Research Foundation | Compositions and methods for cancer detection and treatment |
PE20151501A1 (es) | 2012-12-21 | 2015-11-08 | Epizyme Inc | Inhibidores de prmt5 y sus usos |
JP2016505002A (ja) | 2012-12-21 | 2016-02-18 | エピザイム,インコーポレイティド | ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するprmt5阻害剤およびその使用 |
JP2016505001A (ja) | 2012-12-21 | 2016-02-18 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
US8906900B2 (en) | 2012-12-21 | 2014-12-09 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
US10118918B2 (en) | 2012-12-21 | 2018-11-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
GB201302927D0 (en) | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
CA2942833A1 (en) | 2013-03-15 | 2014-09-18 | Ohio State Innovation Foundation | Inhibitors of prmt5 and methods of their use |
US20170198006A1 (en) | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
WO2015200677A2 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
PE20170146A1 (es) | 2014-06-25 | 2017-03-08 | Glaxosmithkline Ip Dev Ltd | Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carboxamida |
CA2953572A1 (en) | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
US10005792B2 (en) | 2014-09-03 | 2018-06-26 | Ctxt Pty. Ltd. | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors |
GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
WO2016034673A1 (en) | 2014-09-03 | 2016-03-10 | Ctxt Pty Ltd | Tetrahydroisoquinoline derived prmt5-inhibitors |
WO2016038550A1 (en) | 2014-09-11 | 2016-03-17 | Novartis Ag | Inhibition of prmt5 to treat mtap-deficiency-related diseases |
US10479997B2 (en) * | 2014-12-01 | 2019-11-19 | Novartis Ag | Compositions and methods for diagnosis and treatment of prostate cancer |
CR20170384A (es) | 2015-02-24 | 2017-11-16 | Pfizer | Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos |
WO2016145150A2 (en) | 2015-03-11 | 2016-09-15 | The Broad Institute Inc. | Selective treatment of prmt5 dependent cancer |
AR104326A1 (es) | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
TWI791251B (zh) * | 2015-08-26 | 2023-02-01 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
CN110167928A (zh) * | 2016-12-22 | 2019-08-23 | 勃林格殷格翰国际有限公司 | 作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物 |
EA201990851A1 (ru) * | 2017-02-24 | 2019-09-30 | Янссен Фармацевтика Нв | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 |
ES2885180T3 (es) * | 2017-08-09 | 2021-12-13 | Prelude Therapeutics Inc | Inhibidores selectivos de la proteína arginina metiltransferasa 5 (PRMT5) |
CA3074690A1 (en) * | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
PL3724190T3 (pl) * | 2017-12-13 | 2022-10-31 | Lupin Limited | Podstawione bicykliczne związki heterocykliczne jako inhibitory PRMT5 |
-
2020
- 2020-10-22 CN CN202080073338.3A patent/CN114599361A/zh active Pending
- 2020-10-22 IL IL292229A patent/IL292229A/en unknown
- 2020-10-22 MX MX2022004917A patent/MX2022004917A/es unknown
- 2020-10-22 PE PE2022000657A patent/PE20221154A1/es unknown
- 2020-10-22 BR BR112022007808A patent/BR112022007808A2/pt unknown
- 2020-10-22 WO PCT/IB2020/059921 patent/WO2021079302A1/en active Application Filing
- 2020-10-22 JP JP2022524048A patent/JP2023504230A/ja active Pending
- 2020-10-22 KR KR1020227016800A patent/KR20220086628A/ko unknown
- 2020-10-22 US US17/767,270 patent/US20220395508A1/en active Pending
- 2020-10-22 CR CR20220175A patent/CR20220175A/es unknown
- 2020-10-22 CA CA3156135A patent/CA3156135A1/en active Pending
- 2020-10-22 EP EP20803923.0A patent/EP4048270A1/en active Pending
- 2020-10-22 AU AU2020371295A patent/AU2020371295A1/en active Pending
-
2022
- 2022-04-01 ZA ZA2022/03770A patent/ZA202203770B/en unknown
- 2022-04-21 EC ECSENADI202232209A patent/ECSP22032209A/es unknown
- 2022-04-22 CO CONC2022/0005053A patent/CO2022005053A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2022004917A (es) | 2022-08-04 |
WO2021079302A1 (en) | 2021-04-29 |
ECSP22032209A (es) | 2022-05-31 |
KR20220086628A (ko) | 2022-06-23 |
CN114599361A (zh) | 2022-06-07 |
ZA202203770B (en) | 2022-12-21 |
AU2020371295A1 (en) | 2022-04-28 |
IL292229A (en) | 2022-06-01 |
BR112022007808A2 (pt) | 2022-07-05 |
CA3156135A1 (en) | 2021-04-29 |
JP2023504230A (ja) | 2023-02-02 |
PE20221154A1 (es) | 2022-07-18 |
EP4048270A1 (en) | 2022-08-31 |
CO2022005053A2 (es) | 2022-04-29 |
US20220395508A1 (en) | 2022-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022004917A (es) | Combinación farmacéutica de inhibidores de prmt5. | |
AU2017382297A8 (en) | Phosphodiesterase inhibitors and methods of microbial treatment | |
MX2018001351A (es) | Inhibidores de los puntos de control inmunitarios para su uso en el tratamiento del cancer hematologico. | |
MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
TW201613644A (en) | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor | |
WO2007057457A3 (en) | Neuroendocrine tumor treatment using mtor inhibitors | |
ATE356804T1 (de) | Inhibitoren von mitotischem kinesin | |
SG10201909199PA (en) | Method for treating cancer | |
MX346379B (es) | Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (cdk4/6) y un inhibidor de mtor para tratar cancer. | |
ATE421512T1 (de) | Inhibitoren von mitotischem kinesin | |
NZ721280A (en) | Pharmaceutical compositions and methods for treating cancer | |
BRPI0410331A (pt) | método para tratar doença de disco degenerativa | |
SA519410093B1 (ar) | مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز | |
MX2021016049A (es) | Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas. | |
JOP20210193A1 (ar) | مثبطات pcsk9 وطرق استخدامها | |
ATE437653T1 (de) | Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika | |
WO2015095838A3 (en) | Cancer treatments using combinations of mek type i and erk inhibitors | |
MX2022008208A (es) | Terapia de combinación que comprende inhibidores de a2a/a2b y proteína de muerte programada 1 /ligando de muerte programada 1 (pd-1/pdl1). | |
MX2022006932A (es) | Combinaciones de inhibidores de diacilglicerol cinasas (dgk) y antagonistas de puntos de control. | |
MX2019003317A (es) | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). | |
PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
WO2008063760A3 (en) | Methods for treating cancer targeting transglutaminase | |
MX2021011524A (es) | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. | |
ZA201901367B (en) | Inhibition of olig2 activity | |
MX2022003001A (es) | Metodos para tratar el cancer mediante el uso de inhibidores del eje de pd-1 y anticuerpos anti-periostina. |